Optimal regimen of cisplatin in squamous cell carcinoma of head and neck yet to be determined.
作者信息
Le Xiuning, Hanna Ehab Y
机构信息
Department of Thoracic and Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Department of Head and Neck Surgery, Division of Surgery, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Ann Transl Med. 2018 Jun;6(11):229. doi: 10.21037/atm.2018.05.10.
Abstract
摘要
相似文献
1
Optimal regimen of cisplatin in squamous cell carcinoma of head and neck yet to be determined.
Ann Transl Med. 2018 Jun;6(11):229. doi: 10.21037/atm.2018.05.10.
2
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
BMC Cancer. 2016 Nov 25;16(1):918. doi: 10.1186/s12885-016-2957-y.
3
In squamous cell head and neck cancer: which platinum, how much and how often?
Expert Rev Anticancer Ther. 2014 Sep;14(9):1033-9. doi: 10.1586/14737140.2014.924399. Epub 2014 Jul 6.
4
Response Rate of Cisplatin Plus Docetaxel as Primary Treatment in Locally Advanced Head and Neck Carcinoma (Squamous Cell Types).
Asian Pac J Cancer Prev. 2020 Mar 1;21(3):825-830. doi: 10.31557/APJCP.2020.21.3.825.
5
The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma.
Eur Arch Otorhinolaryngol. 2017 Oct;274(10):3757-3765. doi: 10.1007/s00405-017-4687-4. Epub 2017 Jul 28.
6
Induction chemotherapy with cisplatin and ifosfamide in locally advanced inoperable squamous cell carcinoma of the head and neck: A single-institution experience.
Indian J Cancer. 2016 Jul-Sep;53(3):372-376. doi: 10.4103/0019-509X.200661.
7
A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
Oncologist. 2019 Jun;24(6):751-e231. doi: 10.1634/theoncologist.2019-0070. Epub 2019 Feb 22.
8
Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group.
Ann Oncol. 1994 Jul;5(6):521-6. doi: 10.1093/oxfordjournals.annonc.a058906.
9
The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
Clin Oncol (R Coll Radiol). 2013 Nov;25(11):647-53. doi: 10.1016/j.clon.2013.07.007. Epub 2013 Aug 13.
10
and variations in outcomes of tobacco- and alcohol-related head and neck squamous cell carcinoma patients.
Tumour Biol. 2020 Jul;42(7):1010428320938494. doi: 10.1177/1010428320938494.
引用本文的文献
1
Successful Treatment of an Advanced Larynx Carcinoma Using Neo-Adjuvant Chemo-Immunotherapy and Cisplatin/Radiotherapy for a Patient with Rendu-Osler Disease.
J Clin Med. 2025 Aug 12;14(16):5694. doi: 10.3390/jcm14165694.
2
A Targeted Radiotheranostic Agent for Glioblastoma: [Cu]Cu-NOTA-TP-c(RGDfK).
Brain Sci. 2025 Aug 7;15(8):844. doi: 10.3390/brainsci15080844.
3
At-home 1-week hydration improves tolerance and treatment intensity of high-dose cisplatin in locally advanced head and neck cancer: a retrospective study.
Support Care Cancer. 2025 Jun 3;33(6):530. doi: 10.1007/s00520-025-09597-1.
4
Retrospective study of cisplatin plus radiotherapy toxicities in locally advanced squamous cell carcinoma of the head and neck - ReCisTT study.
Front Oncol. 2024 Oct 14;14:1220640. doi: 10.3389/fonc.2024.1220640. eCollection 2024.
5
Efficacy of Quercetin and Quercetin Loaded Chitosan Nanoparticles Against Cisplatin-Induced Renal and Testicular Toxicity via Attenuation of Oxidative Stress, Inflammation, and Apoptosis.
Pharmaceuticals (Basel). 2024 Oct 17;17(10):1384. doi: 10.3390/ph17101384.
6
Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II/III trial of JCOG1008.
Cancer Med. 2024 Sep;13(18):e70235. doi: 10.1002/cam4.70235.
7
Anti-cancer management of head and neck cancers and oral microbiome-what can we clinically obtain?
Front Cell Infect Microbiol. 2024 Feb 28;14:1329057. doi: 10.3389/fcimb.2024.1329057. eCollection 2024.
8
The emerging role of oral microbiota in oral cancer initiation, progression and stemness.
Front Immunol. 2023 Oct 26;14:1198269. doi: 10.3389/fimmu.2023.1198269. eCollection 2023.
9
Enhanced efficacy in drug-resistant cancer cells through synergistic nanoparticle mediated delivery of cisplatin and decitabine.
Nanoscale Adv. 2020 Jan 27;2(3):1177-1186. doi: 10.1039/c9na00684b. eCollection 2020 Mar 17.
10
Genetically Engineered Nanoparticles of Asymmetric Triblock Polypeptide with a Platinum(IV) Cargo Outperforms a Platinum(II) Analog and Free Drug in a Murine Cancer Model.
Nano Lett. 2022 Jul 27;22(14):5898-5908. doi: 10.1021/acs.nanolett.2c01850. Epub 2022 Jul 15.
本文引用的文献
1
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
J Clin Oncol. 2018 Apr 10;36(11):1064-1072. doi: 10.1200/JCO.2017.74.9457. Epub 2017 Dec 8.
2
[GLOBAL INCIDENCE AND RISK FACTORS OF ORAL CANCER].
Harefuah. 2017 Oct;156(10):645-649.
3
NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.
J Natl Compr Canc Netw. 2017 Jun;15(6):761-770. doi: 10.6004/jnccn.2017.0101.
4
Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual.
CA Cancer J Clin. 2017 Mar;67(2):122-137. doi: 10.3322/caac.21389. Epub 2017 Jan 27.
5
Continuing rise in oropharyngeal cancer in a high HPV prevalence area: A Danish population-based study from 2011 to 2014.
Eur J Cancer. 2017 Jan;70:75-82. doi: 10.1016/j.ejca.2016.10.015. Epub 2016 Nov 23.
6
Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study.
Lancet Oncol. 2016 Apr;17(4):440-451. doi: 10.1016/S1470-2045(15)00560-4. Epub 2016 Feb 27.
7
Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma.
J Clin Oncol. 2015 Oct 10;33(29):3235-42. doi: 10.1200/JCO.2015.61.6995. Epub 2015 Sep 8.
8
Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review.
Head Neck. 2016 Apr;38 Suppl 1:E2151-8. doi: 10.1002/hed.24026. Epub 2015 Jul 14.
9
Trends in head and neck cancers in England from 1995 to 2011 and projections up to 2025.
Oral Oncol. 2015 Apr;51(4):341-8. doi: 10.1016/j.oraloncology.2015.01.002. Epub 2015 Jan 22.
10
Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.
J Clin Oncol. 2014 Dec 1;32(34):3858-66. doi: 10.1200/JCO.2014.55.3925. Epub 2014 Nov 3.
Zotero 插件